JP2011505349A - 肥満細胞活性化の阻害用組成物を製造するためのエル・カゼイ株の使用 - Google Patents

肥満細胞活性化の阻害用組成物を製造するためのエル・カゼイ株の使用 Download PDF

Info

Publication number
JP2011505349A
JP2011505349A JP2010535473A JP2010535473A JP2011505349A JP 2011505349 A JP2011505349 A JP 2011505349A JP 2010535473 A JP2010535473 A JP 2010535473A JP 2010535473 A JP2010535473 A JP 2010535473A JP 2011505349 A JP2011505349 A JP 2011505349A
Authority
JP
Japan
Prior art keywords
casei
composition
bacteria
use according
bmmc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010535473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505349A5 (https=
Inventor
シファー−マニウィ，セシル
デロン，マルク
サムソン，サンドリーヌ
ブールデ−シカール，ラファエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gervais Danone SA
Institut Pasteur
Original Assignee
Gervais Danone SA
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone SA, Institut Pasteur filed Critical Gervais Danone SA
Publication of JP2011505349A publication Critical patent/JP2011505349A/ja
Publication of JP2011505349A5 publication Critical patent/JP2011505349A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
JP2010535473A 2007-11-30 2008-12-01 肥満細胞活性化の阻害用組成物を製造するためのエル・カゼイ株の使用 Pending JP2011505349A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291431A EP2065048A1 (en) 2007-11-30 2007-11-30 Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
PCT/IB2008/003690 WO2009068997A1 (en) 2007-11-30 2008-12-01 Use of a l. casei strain, for the preparation of a composition for inhibiting mast cell activation

Publications (2)

Publication Number Publication Date
JP2011505349A true JP2011505349A (ja) 2011-02-24
JP2011505349A5 JP2011505349A5 (https=) 2012-01-26

Family

ID=39323735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535473A Pending JP2011505349A (ja) 2007-11-30 2008-12-01 肥満細胞活性化の阻害用組成物を製造するためのエル・カゼイ株の使用

Country Status (7)

Country Link
US (1) US20100284973A1 (https=)
EP (2) EP2065048A1 (https=)
JP (1) JP2011505349A (https=)
CN (1) CN101909643A (https=)
AR (1) AR069520A1 (https=)
RU (1) RU2010126596A (https=)
WO (1) WO2009068997A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505162A (ja) * 2007-12-04 2011-02-24 コンパニ・ジェルベ・ダノン 抗真菌剤としてのエル・カゼイ亜種パラカゼイの使用
WO2019139434A1 (ko) * 2018-01-12 2019-07-18 (주)지아이이노베이션 프로바이오틱스 및 ige에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
US20130121976A1 (en) * 2010-03-12 2013-05-16 Agusti Montserrat Carreras Lactic Acid Bacteria for Coeliac Disease
KR101275227B1 (ko) * 2010-10-13 2013-06-18 광주과학기술원 중증근무력증 예방, 개선 또는 치료용 조성물
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN103257237B (zh) * 2013-05-09 2015-05-20 中国农业大学 一种食品中过敏原的体外检测方法
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
ME03511B (me) * 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN109312297B (zh) * 2015-12-11 2022-09-23 精密生物集团有限公司 用于治疗肥胖症和相关代谢病的干酪乳杆菌
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
ES2877726T3 (es) 2017-05-22 2021-11-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
CN109266584B (zh) * 2018-10-18 2020-09-08 扬州大学 一株具有肥大细胞活性调节作用的纤毛型鼠李糖乳杆菌及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242532A (ja) * 1988-03-25 1989-09-27 Yakult Honsha Co Ltd 抗体産生増強型免疫賦活剤
JP2003514869A (ja) * 1999-11-19 2003-04-22 プロビオール・プロプライエタリー・リミテッド アレルギー性疾患の処置のための組成物および方法
JP2005508150A (ja) * 2001-07-26 2005-03-31 アリメンタリー・ヘルス・リミテッド プロバイオティックラクトバチラスカゼイ株類
EP1683425A1 (en) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction
JP2007508838A (ja) * 2003-10-24 2007-04-12 ナムローゼ フェンノートシャップ ニュートリシア 乳児向けシンバイオティック組成物
JP2007117031A (ja) * 2005-10-31 2007-05-17 Nakagaki Gijutsushi Jimusho:Kk インターフェロンガンマ発現誘導作用を有する発酵乳、及び発酵乳製造用種菌

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1099271A (zh) * 1993-08-23 1995-03-01 王世荣 生态口服液
CN1114354A (zh) * 1994-06-23 1996-01-03 江苏省纺织(集团)总公司实业开发分公司 双歧杆菌在含中药培养基中进行有氧发酵的方法
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
CN1289092C (zh) * 2002-10-29 2006-12-13 西安大鹏生物科技股份有限公司 一种肠道微生态调节剂
FR2848115B1 (fr) * 2002-12-05 2005-03-25 Rhodia Chimie Sa Composition de bacteries et son utilisation
CN100396771C (zh) * 2004-05-10 2008-06-25 景岳生物科技股份有限公司 新的微生物株类干酪乳杆菌gm-080及其治疗过敏相关疾病的用途
US7351572B2 (en) * 2004-10-15 2008-04-01 Genmont Biotech Inc. Microorganism strain GM-090 of Lactobacillus fermentum and its use for stimulating IFN-γ secretion and/or treating allergy
WO2007035057A1 (en) * 2005-09-23 2007-03-29 Gwangju Institute Of Science And Technology Composition for preventing or treating artritis comprising lactic acid bacteria and collangen as active ingredients
CN100556414C (zh) * 2005-10-14 2009-11-04 德阳创新生物工程有限公司 一种具免疫调节功能的多菌组合物及其制备方法与用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242532A (ja) * 1988-03-25 1989-09-27 Yakult Honsha Co Ltd 抗体産生増強型免疫賦活剤
JP2003514869A (ja) * 1999-11-19 2003-04-22 プロビオール・プロプライエタリー・リミテッド アレルギー性疾患の処置のための組成物および方法
JP2005508150A (ja) * 2001-07-26 2005-03-31 アリメンタリー・ヘルス・リミテッド プロバイオティックラクトバチラスカゼイ株類
JP2007508838A (ja) * 2003-10-24 2007-04-12 ナムローゼ フェンノートシャップ ニュートリシア 乳児向けシンバイオティック組成物
EP1683425A1 (en) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction
JP2007117031A (ja) * 2005-10-31 2007-05-17 Nakagaki Gijutsushi Jimusho:Kk インターフェロンガンマ発現誘導作用を有する発酵乳、及び発酵乳製造用種菌

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6013036107; ＦＥＭＳ　Ｉｍｍｕｎｏｌｏｇｙ　ａｎｄ　Ｍｅｄｉｃａｌ　Ｍｉｃｒｏｂｉｏｌｏｇｙ Ｖｏｌ．４５，　Ｎｏ．２, 2005, ｐ．２５９-２６７ *
JPN6013036110; Ｌｉｆｅ　Ｓｃｉｅｎｃｅｓ Ｖｏｌ．６３，　Ｎｏ．８, 1998, ｐ．６３５-６４４ *
JPN6013036113; Ｅｎｄｏｃｒｉｎｅ　Ｊｏｕｒｎａｌ Ｖｏｌ．４４，　Ｎｏ．３, 1997, ｐ．３５７-３６５ *
JPN6013036114; Ｎｕｔｒｉｔｉｏｎ Ｖｏｌ．２３，　Ｎｏ．１, 200701, ｐ．６２-６８ *
JPN6013036116; 食の科学 Ｎｏ．３２１, 2004, ｐ．３０-３５ *
JPN6013036118; 栄養-評価と治療 Ｖｏｌ．１６，　Ｎｏ．３, 1999, ｐ．５９-６５ *
JPN6013036119; Ｂｉｏｓｃｉｅｎｃｅ　Ｍｉｃｒｏｆｌｏｒａ Ｖｏｌ．１９，　Ｎｏ．１, 2000, ｐ．１-８ *
JPN6013036122; アレルギー Ｖｏｌ．５２，　Ｎｏ．１, 2003, ｐ．２０-３０ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505162A (ja) * 2007-12-04 2011-02-24 コンパニ・ジェルベ・ダノン 抗真菌剤としてのエル・カゼイ亜種パラカゼイの使用
WO2019139434A1 (ko) * 2018-01-12 2019-07-18 (주)지아이이노베이션 프로바이오틱스 및 ige에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도
US12128076B2 (en) 2018-01-12 2024-10-29 Gi Innovation, Inc. Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof

Also Published As

Publication number Publication date
US20100284973A1 (en) 2010-11-11
RU2010126596A (ru) 2012-01-10
WO2009068997A1 (en) 2009-06-04
EP2065048A1 (en) 2009-06-03
CN101909643A (zh) 2010-12-08
AR069520A1 (es) 2010-01-27
EP2224936A1 (en) 2010-09-08

Similar Documents

Publication Publication Date Title
JP2011505349A (ja) 肥満細胞活性化の阻害用組成物を製造するためのエル・カゼイ株の使用
Finamore et al. Supplementation with Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13 mixture improves immunity in elderly humans (over 75 years) and aged mice
JP6608047B2 (ja) 多様な機能性を有する新規乳酸菌およびその用途
Lim et al. Weissella cibaria WIKIM28 ameliorates atopic dermatitis-like skin lesions by inducing tolerogenic dendritic cells and regulatory T cells in BALB/c mice
De Kivit et al. Regulation of intestinal immune responses through TLR activation: implications for pro-and prebiotics
Hacini-Rachinel et al. Oral probiotic control skin inflammation by acting on both effector and regulatory T cells
Boirivant et al. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis
EP3097927B1 (en) A method of inducing tolerance to an allergen
Roselli et al. Beneficial effects of a selected probiotic mixture administered to high fat-fed mice before and after the development of obesity
Zhou et al. Are there potential applications of fecal microbiota transplantation beyond intestinal disorders?
JP2010523144A (ja) アテローム性動脈硬化症を軽減するための、選択された乳酸菌の使用
JP2003514869A (ja) アレルギー性疾患の処置のための組成物および方法
CA3154308A1 (en) Compositions and methods for treating autism spectrum disorder
KR100913406B1 (ko) Ｔｈ１－매개 면역 질환의 예방 또는 치료용 조성물
Ogita et al. Streptococcus thermophilus ST28 ameliorates colitis in mice partially by suppression of inflammatory Th17 cells
JP6901092B2 (ja) 多様な機能性を有する新規乳酸菌およびその用途
Qiao et al. Fermentation products of Paenibacillus bovis sp. nov. BD3526 alleviates the symptoms of type 2 diabetes mellitus in GK rats
Banoth et al. The Role of Oral Probiotics in Alleviating Inflammation, Symptom Relief, and Postoperative Recurrence and Their Side Effects in Adults With Crohn's Disease: A Systematic Review
US20100028263A1 (en) Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
JP2009510053A (ja) 桂皮抽出物を有効成分として含む腸内菌叢改善及び免疫機能増進用組成物
US11622981B2 (en) Bacterial strain useful for treatment of age-related conditions
Lockyer et al. The role of probiotics on the roadmap to a healthy microbiota: a symposium report
Grumezescu et al. Diet, microbiome and health
Janakiraman Regulation of spontaneous CNS autoimmunity by dietary salt
Türker et al. Anti-inflammatory effects of probiotics and their metabolites: Possible role for epigenetic effects

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150116

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150320

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150515